Understand the source comparison
How to Use Peptides for Chronic Pain: Protocol Comparison
This table compares three peptide protocols commonly used in chronic pain research models, showing dosing, administration frequency, and primary mechanisms. BPC-157 250–500mcg Daily Reduces inflammatory cytokines (TNF-α, IL-1β), promotes angiogenesis via VEGF
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares three peptide protocols commonly used in chronic pain research models, showing dosing, administration frequency, and primary mechanisms.
- BPC-157
- 250–500mcg
- Daily
- Reduces inflammatory cytokines (TNF-α, IL-1β), promotes angiogenesis via VEGF upregulation, stabilizes nitric oxide pathways
- Inflammatory, nociceptive
- 10–14 days for biomarker changes; 4–6 weeks for behavioral pain reduction
- Best-documented compound for tissue-level pain mechanisms; consistent results across injury models
- Thymosin Beta-4
- 2–5mg
- Twice weekly
- Suppresses substance P and CGRP release, promotes oligodendrocyte differentiation and myelin repair
- Neuropathic
- 14–21 days for allodynia reduction; 6–8 weeks for sustained neuroprotection
- Strongest evidence for nerve injury pain; higher cost per dose limits accessibility
- KPV
- 500mcg–1mg
- Inhibits NF-κB signaling, suppresses IL-6, TNF-α, and IL-1β in macrophages and microglia
- Neuroinflammatory
- 7–10 days for cytokine suppression; 3–4 weeks for pain score reduction
- Underutilized in pain research despite strong anti-inflammatory data; oral bioavailability remains contested